SECOND AMENDED AND RESTATED TERM LOAN AGREEMENT dated as of May 15, 2018 between CORREVIO PHARMA CORP. as Borrower, The Subsidiary Guarantors from Time to Time Party Hereto, The Lenders from Time to Time Party Hereto, and CRG SERVICING LLC as...Term Loan Agreement • July 12th, 2018 • Correvio Pharma Corp. • Pharmaceutical preparations • New York
SECOND AMENDED AND RESTATED TERM LOAN AGREEMENT, dated as of May 15, 2018 (this “Agreement”), among CORREVIO PHARMA CORP., a corporation incorporated pursuant to the federal laws of Canada (“Borrower”), the Subsidiary Guarantors from time to time party hereto, the Lenders from time to time party hereto and CRG SERVICING LLC, a Delaware limited liability company (“CRG Servicing”), as administrative and collateral agent for the Lenders (in such capacities, together with its successors and assigns, “Administrative Agent”).
CIPHER PHARMACEUTICALS INC. and CARDIOME PHARMA CORP. and CORREVIO PHARMA CORP. ARRANGEMENT AGREEMENT March 19, 2018Arrangement Agreement • July 12th, 2018 • Correvio Pharma Corp. • Pharmaceutical preparations • British Columbia
Arrangement Agreement dated March 19, 2018 among Cipher Pharmaceuticals Inc. (“Cipher”), Cardiome Pharma Corp. (“Cardiome”) and Correvio Pharma Corp. (“Correvio”).
LICENSE AGREEMENT Dated as of May 5, 2016 by and between DURATA THERAPEUTICS INTERNATIONAL B.V. and CORREVIO INTERNATIONAL SÁRLLicense Agreement • July 12th, 2018 • Correvio Pharma Corp. • Pharmaceutical preparations • New York
This License Agreement (this "Agreement"), effective as of May 5, 2016 (the "Effective Date"), is made by and between Durata Therapeutics International B.V., a private limited company registered in the Netherlands with offices at Barbara Strozzilaan 101, Spaces Zuida, Amsterdam, the Netherlands ("Allergan"), and Correvio International Sárl, a Swiss corporation with offices at Rue des Alpes 21, Case postale 1674, 1201 Geneva, Switzerland ("Licensee"). Each of Allergan and Licensee is referred to herein individually as a "Party" and collectively as the "Parties." Certain capitalized terms have the meanings provided in Article I below.
Exclusive License and Supply Agreement by and between Cardiome Pharma Corp. and Correvio International Sárl and SteadyMed Ltd.Exclusive License and Supply Agreement • July 12th, 2018 • Correvio Pharma Corp. • Pharmaceutical preparations • New York
This Exclusive License and Supply Agreement (this “Agreement”) is made as of 28th June 2015 (the “Effective Date”), by and between Cardiome Pharma Corp., a company duly incorporated under the laws of Canada, with its principal place of business at 1441 Creekside Drive, 6th Floor, Vancouver BC V6J 4S7 and Correvio International Sàrl, a company duly incorporated and existing under the laws of Switzerland, with its principal place of business at Rue des Alpes 21, 1201 Geneva, Switzerland (hereinafter collectively referred to as “Cardiome”), and SteadyMed Ltd., a company organized and existing under the laws of Israel with its principal place of business at 5 Oppenheimer Street, Rehovot 7670105, Israel (“SteadyMed”). Each of Cardiome and SteadyMed is referred to individually as a “Party” and collectively as the “Parties”.
SUPPLY AGREEMENT Dated as of May 5, 2016 by and between DURATA THERAPEUTICS INTERNATIONAL B.V. and CORREVIO INTERNATIONAL SÁRLSupply Agreement • July 12th, 2018 • Correvio Pharma Corp. • Pharmaceutical preparations • New York
This Supply Agreement (this "Agreement"), dated as of May 5, 2016 (the "Effective Date"), is made by and between Correvio International Sárl, a Swiss corporation with offices at Rue des Alpes 21, Case postale 1674, 1201 Geneva, Switzerland ("Licensee"), and Durata Therapeutics International B.V., a company registered in the Netherlands with offices at Spaces Zuidas II, Barbara Strozzilaan 101, 1083 HN Amsterdam, the Netherlands ("Allergan"). Each of Licensee and Allergan is referred to herein individually as a "Party" and collectively as the "Parties." Certain capitalized terms have the meanings provided in Article I below.
